Respiratory Video Recap—February 20, 2026

This biweekly Respiratory Video Recap summarizes key developments including regulatory actions, clinical progress, data releases, and strategic partnerships that have shaped the field in recent weeks.

🎯 Watch Our Video Summary Capturing Respiratory News from the Last Two Weeks

🗓️ Explore weekly details and sources

Week 6–12 February 2026
Week 13–19 February 2026

📚 See the full Respiratory archive on our research hub page.

Transcript

Welcome to the latest edition of Respiratory Research Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

Pulmovant has announced the completion of Phase 2 PHocus study enrollment for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The topline results from this study are expected in the second half of 2026, which could provide a potential new treatment option for patients suffering from this condition, significantly impacting the current treatment landscape.

In preclinical research, Devonian has reported promising results for its drug candidate Thykamine™ in pulmonary fibrosis. In animal models, Thykamine™ demonstrated stronger antifibrotic effects than pirfenidone, suggesting that it could provide a more effective treatment for pulmonary fibrosis, a progressive and often debilitating disease.

Kymera Therapeutics has shared insights into the potential of its drug candidate KT-621 for the treatment of asthma, presented at the Guggenheim Biotech Summit. KT-621 is an oral STAT6 degrader that targets IL-4 and IL-13 signaling, which plays a crucial role in Type II inflammation in asthma. The development of KT-621 could revolutionize asthma treatment by offering a biologic-like effect in an oral formulation, making it more convenient for patients.

Eradivir has entered the next phase of development for its lead candidate EV148, which is aimed at treating respiratory syncytial virus (RSV). The company has initiated IND-enabling studies, and EV148 shows a novel mechanism by recruiting the immune system to fight RSV, offering a potential solution for treating both early and late-stage infections. This approach could address unmet needs in RSV treatment, broadening its therapeutic window.

AstraZeneca has reported positive Phase III results for its asthma treatment Breztri Aerosphere, showing improvements in lung function and a reduction in asthma exacerbations. These results, published in The Lancet Respiratory Medicine, demonstrate that Breztri outperformed dual therapies in patient outcomes, positioning it as a promising option for patients with uncontrolled asthma.

Sanofi’s Beyfortus study shows that immunization with Beyfortus offers lasting protection against RSV-related hospitalizations in infants. The study found that immunization in the first season reduced hospitalizations in the second season by more than 50%. Beyfortus could have a significant impact on global RSV prevention strategies for infants, potentially reshaping how the virus is managed.

Boehringer Ingelheim has decided to halt its gene therapy trial for cystic fibrosis following disappointing data. The trial failed to meet the necessary efficacy benchmarks, leading to the termination of the study. This outcome has significant implications for the future of gene therapy in complex diseases like cystic fibrosis.

Zydus Lifesciences has received USFDA approval for Bosentan oral suspension for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged 3 and older. This approval expands treatment options for children with PAH, offering a new approach to managing this rare and life-threatening condition in the pediatric population.

Stay ahead in Respiratory Research! Like, share, and subscribe for our updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

Pulmonary Hypertension: Pulmovant’s rapid Phase 2 PHocus study enrollment could lead to new treatment options for PH-ILD patients.
Pulmonary Fibrosis: Devonian’s preclinical results with Thykamine™ offer hope for more effective pulmonary fibrosis therapies.
Oral Treatments in Asthma: Kymera’s KT-621 may offer biologic-like effects in an oral form, making treatment more convenient for asthma patients.
RSV Treatment: Eradivir’s EV148 and Sanofi’s Beyfortus could revolutionize RSV treatment with extended efficacy and immune system recruitment.
Uncontrolled Asthma: AstraZeneca’s Breztri could set a new standard for treating uncontrolled asthma, offering significant benefits over dual therapies.
Cystic Fibrosis Gene Therapy: Boehringer’s gene therapy failure highlights the challenges in gene therapy development for complex diseases like cystic fibrosis.
Pediatric PAH Treatment: Zydus’s approval of Bosentan for children with PAH improves treatment options for this vulnerable group.

🗓️ Explore weekly details and sources

Week 6–12 February 2026
Week 13–19 February 2026

📚 See the full Respiratory archive on our research hub page.

FAQ

What is Pulmovant’s next step after Phase 2 PHocus enrollment?

Pulmovant will report topline results from the Phase 2 PHocus study in the second half of 2026, which could provide a new treatment option for PH-ILD.

How does Thykamine™ compare to pirfenidone in pulmonary fibrosis?

Thykamine™ showed stronger antifibrotic effects in preclinical studies compared to pirfenidone, positioning it as a promising candidate for pulmonary fibrosis treatment.

What is KT-621’s potential for asthma?

KT-621 aims to offer oral biologic-like effects for asthma, which could significantly improve treatment adherence and patient convenience.

How does EV148 work for RSV treatment?

EV148 recruits existing antibodies in the body to target RSV-infected cells, offering potential for both early and late-stage infection treatment.

What did AstraZeneca’s Breztri trial results show?

Breztri showed statistically significant improvements in lung function and reduced asthma exacerbations, making it a potential new standard of care for uncontrolled asthma.

What impact could Beyfortus have on RSV prevention?

Beyfortus offers long-term protection against RSV, reducing hospitalizations in the second season, which could reshape RSV prevention strategies globally.

Entities / Keywords

Pulmovant: PH-ILD, mosliciguat, Phase 2 PHocus, pulmonary hypertension
Devonian: Thykamine™, pulmonary fibrosis, preclinical
Kymera Therapeutics: KT-621, asthma, Type II diseases, Guggenheim Summit
Eradivir: EV148, RSV, preclinical efficacy, BAiT platform
AstraZeneca: Breztri, Phase III, asthma, lung function
Sanofi: Beyfortus, RSV, infant immunization
Boehringer Ingelheim: cystic fibrosis, gene therapy, BI 3720931
Zydus Lifesciences: Bosentan, PAH, pediatric approval, USFDA

References

https://www.pulmovant.com/press-release-february-6-2026
https://groupedevonian.com/devonian-reports-positive-results-in-pulmonary-fibrosis-study/
https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-first-patient-dosed-breadth-phase
https://eradivir.com/wp-content/uploads/2026-02-12-Eradivir-RSV-Candidate.pdf
https://www.astrazeneca.com/media-centre/press-releases/2026/positive-and-clinically-meaningful-results-from-the-phase-iii-kalos-and-logos-trials-for-breztri.html
https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-16-06-00-00-3238527
https://www.fiercebiotech.com/biotech/boehringer-axes-inhaled-gene-therapy-after-viewing-cystic-fibrosis-data
https://zyduslife.com/investor/admin/uploads/21/83/Zydus-receives-final-approval-from-USFDA-for-Bosentan-tablets-for-oral-suspension–32-mg.pdf